News

Cognition Therapeutics Advances Zervimesine Program for DLB Treatment

Cognition Therapeutics Advances Zervimesine Program for DLB Treatment

Cognition Therapeutics Achieves Enrollment Milestone in DLB Treatment

Cognition Therapeutics, Inc. (NASDAQ: CGTX) has recently announced a significant achievement in their clinical efforts to combat dementia with Lewy bodies (DLB). The company's expanded access program for zervimesine (CT1812) has now reached full enrollment, marking an important milestone in the ongoing battle against neurodegenerative disorders. This undertaking provides eligible participants the opportunity to receive 100 mg of this innovative treatment daily for up to one year, greatly improving their access to potential therapeutic benefits.

The expansion of this program was made possible thanks to the generous support from a family of a participant involved in the earlier Phase 2 SHIMMER study of zervimesine. Lisa Ricciardi, the president and CEO of Cognition Therapeutics, stated, "We are grateful to the family who made it possible to provide expanded access to zervimesine for people who were in the Phase 2 DLB study. The efforts of our dedicated investigators and our clinical operations team made it possible to complete enrollment in only three months." This rapid enrollment is reflective of the pressing need for effective treatments among the DLB patient community.

Dr. Lawrence S. Honig, a key investigator and professor of neurology at Columbia University Irving Medical Center, expressed his enthusiasm regarding the significance of this development, noting the keen interest from patients. "The ability to provide our patients with a medication that they feel is making a meaningful difference in their lives is incredibly rewarding," he shared. Dr. Honig is eager to continue collaboration with Cognition Therapeutics as they progress into the next stages of clinical development for zervimesine.

Seeking Regulatory Guidance for Phase 3 Studies

Cognition Therapeutics has successfully aligned with the U.S. Food and Drug Administration (FDA) regarding a registrational program focused on Alzheimer’s disease and is now seeking similar insights for DLB. The company’s application for a Type C meeting with the FDA has been approved, with a meeting scheduled for January. This meeting will delve into the proposed design for a Phase 3 clinical program targeting patients with DLB, with anticipated meeting minutes to follow.

Understanding the Expanded Access Program

The COG1202 expanded access program provides an open-label approach for eligible participants who completed the Phase 2 study, alongside additional patients diagnosed with mild to moderate DLB. This program stands as a crucial lifeline for many in need of therapeutic alternatives. Dr. James E. Galvin from the University of Miami Miller School of Medicine leads this multi-center program, ensuring that patients have access to potentially life-changing treatment options. As zervimesine remains an investigational treatment, it's important to note that it has not yet received regulatory approval, which means its safety and efficacy are still under assessment.

Exploring Zervimesine's Potential

Zervimesine, also referred to as CT1812, is an oral medication indicated for the treatment of specific central nervous system conditions, including Alzheimer's disease and dementia with Lewy bodies. Though these conditions exhibit distinct symptoms, they share a common pathological feature: the accumulation of harmful proteins in the brain (A? and ?-synuclein). This protein build-up can interfere with neuronal function, leading to severe cognitive decline and loss of motor skills.

Existing research demonstrates zervimesine’s ability to disrupt the toxic interactions of these proteins, suggesting a potential to slow disease progression and enhance the quality of life for those afflicted by Alzheimer’s and DLB. Early clinical studies indicate that zervimesine is generally well tolerated, marking it as a promising candidate in the ongoing fight against neurodegeneration.

About Cognition Therapeutics

Cognition Therapeutics, Inc. is at the forefront of discovering innovative therapies aimed at treating age-related degenerative disorders affecting the central nervous system. The company has made significant strides in clinical studies, particularly with their leading candidate, zervimesine (CT1812). Their ongoing Phase 2 START Study concentrates on early Alzheimer’s disease, as well. The unique mechanism of zervimesine—targeting the sigma-2 receptor—distinguishes it from other treatment avenues, offering hope in a challenging therapeutic landscape.

For further information about Cognition Therapeutics and updates on their pipeline, interested parties can visit their official website.

Frequently Asked Questions

What is zervimesine used for?

Zervimesine is an investigational oral medication being studied for the treatment of dementia with Lewy bodies and Alzheimer's disease.

Who qualifies for the expanded access program?

Eligible participants include those who completed the Phase 2 study as well as other patients diagnosed with mild-to-moderate DLB who meet specific enrollment criteria.

What are the benefits of zervimesine?

Zervimesine may help slow the progression of neurodegenerative diseases by interrupting the toxic effects of harmful proteins in the brain.

When is the FDA meeting regarding zervimesine?

The Type C meeting with the FDA is scheduled for January and will discuss the Phase 3 program design for zervimesine in DLB patients.

How can I learn more about Cognition Therapeutics?

Visit the official Cognition Therapeutics website for the latest news, updates, and information regarding their drug pipeline and research.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading